Sign In
Buy ABCL
$5.72
-0.410 (-6.69%)
At Close: Jun 03, 2026
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript
09:51pm, Thursday, 13'th May 2021
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript
AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials
09:31am, Tuesday, 04'th May 2021
AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, has entered clinical trials in patients with mi
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-1
AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration
10:05am, Thursday, 01'st Apr 2021
AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery coll
ABCL Stock Price Increased Over 10% Pre-Market: Why It Happened
06:51am, Tuesday, 30'th Mar 2021
The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has increased by over 10% pre-market. This is why it happened.
AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript
10:50pm, Monday, 29'th Mar 2021
AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript
AbCellera Biologics: A Compounding Machine In Biotech Clothing
02:29am, Monday, 08'th Mar 2021
AbCellera Biologics is a little followed and largely uncovered company. What it is building however is known all throughout the biotech and pharma industries. With the likes of Bill Gates, Peter Thiel
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
03:30pm, Friday, 05'th Mar 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
AbCellera to Present at the SVB Leerink Global Healthcare Conference
04:05pm, Wednesday, 17'th Feb 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.
Why AzurRx BioPharma, Usana Health Are Moving Today
11:47am, Wednesday, 10'th Feb 2021
Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
08:26pm, Tuesday, 09'th Feb 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #EUA--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
07:22am, Wednesday, 27'th Jan 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
07:09am, Tuesday, 26'th Jan 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
F-star Therapeutics: New Biologics Platform For Immunotherapy
11:00am, Thursday, 21'st Jan 2021
F-star Therapeutics: New Biologics Platform For Immunotherapy
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
04:41pm, Tuesday, 19'th Jan 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.
